Medical network February 3 - associated with increased morbidity and mortality, serious challenges facing China's cancer treatment.
Recently, the "daily economic news" reporter from the China association of enterprises with foreign investment in drug research and development industry committee (hereinafter referred to as the RDPAC), according to data from China's treatment of cancer of the availability of new drugs is much less than the developed countries such as America and Britain. Statistics show that in 2010-2014 listed 49 kinds of cancer drugs, only 6 in China's listed for use in patients. At the same time, in China the number of clinical trials research projects related to cancer is less than 1/5 of the us.
Roche, vice President of Chinese medicine square straight told the "daily economic news" reporter, drugs listed is different from the auto industry or computer industry and made can be listed, it is a complex process. On the one hand, the domestic need for examination and approval of clinical trials alone before 30 months or so, last year shortened 8-10 months; On the other hand, in addition to clinical trials, new drug research and development also need to accept the government management, ethics committee approval process, and the doctor is not willing to take time out to into to the new drug research and development of clinical trials.
Colorectal cancer and esophageal cancer clinic burden
Journalists, according to data from the RDPAC, according to the 2015 China cancer statistics estimate 2015 new cancer cases in 2015 cases, accounting for 20% of the world's new cases, 2.81 million cases died.
"Cancer has become a major diseases affect people's lives." RDPAC DiSiJie pointed out that the chief executive of the cancer is a major medical burden of Chinese society.
RDPAC mentioned in the report, the latest research report shows, colorectal cancer and esophageal cancer in China urban areas per capita medical burden, about $10000, the burden of patients with lung cancer and stomach cancer, about $9900, liver cancer and breast cancer of medical expenditure per capita of about $8500.
"These figures is what concept? This burden is very large." Well-known experts, lung cancer treatment, vice President of the people's hospital of guangdong province Wu Yilong truth. According to statistics, in terms of the country, a family is the cost of spending $8500 a year on average, if someone has lung cancer, means that the total one year.
Responsible for regional sales of domestic medicine companies in sichuan people li (a pseudonym) told reporters, imported drugs can improve the patients' survival, and no other domestic substitute drugs, natural high prices. In a very effective for gastrointestinal stromal tumor, leukemia molecular target drugs, for example, a box of 120 24000 yuan, can eat 1 month. Although the imported drugs have been in some provinces into health care, but the patient eat 1 years or three years after the surgery, it would cost not a few.
However, li said, these drugs entering the reimbursement is not expensive, and there are many drugs without reimbursement, even not to enter the Chinese market, can only be purchased through other channels. "Those are for medicine, have a cancer drugs listed at the end of 2015, $12750 a box, pipe for a month, which is reduced down the average person can eat up."
RDPAC pointed out in the report, not just in China, the cancer has caused a huge economic burden to the global. It is estimated that 2010 13.3 million new cancer cases in the world the total cost of $290 billion, by 2030, 21.5 million new cases will lead to the economic burden of $458 billion.
The clinical trials research project is five times in China
The world's largest pharmaceutical market consultancy IMS Health, according to the latest research data from 2010 to 2014, a total of 49 global cancer drugs listed, the number listed on the United States, Britain, 41 and 37 species, respectively, and only six in China.
Li said, the latest and greatest drugs usually concentrated in Europe and the United States a few companies, to protect the innovation, the original medicine usually have 10 to 20 years of patent period, during this time, other countries can only import not imitation. Wu Yilong added to this, China's cancer drug accessibility to India, South Africa, at a level.
Learned, according to China's current drug approval rules, foreign new drug clinical trials in China need to redo, this time at least 3 years to 5 years or more.
In domestic market and in the research of new drugs, in fact, the vast majority are in copying and imitation and combining with the stage. , vice chairman of the standing committee of the 11th National People's Congress sang guowei had pointed out that the domestic 5000 now drug companies, the top ten r&d spending was only 1%, the achievements of less than 2%.
Even for the European and American pharmaceutical giant, new drug research and development is also a full of bumpy road. Bristol-myers squibb China r&d director nguyen card chun said that in the early stage of the drug development, often need to determine the objectives of a research and development to study of related compounds. "We choose is roughly 5000 to 10000 compounds, before clinical trials to 250 compounds, it takes about 3 to 6 years. You need to 6 ~ 7 years will study target compounds from 250 down to five, but still unable to determine the research results is success or failure, can open new drug approval if successful."
Nguyen card chun told reporters, for example, new drug research and development is like fighting the virus, researchers want to learn and progress in frustration. In her experience, according to data from the research on melanoma treatment, there are 96 research and development failure, developed 7 new drugs; Lung cancer underwent 167 research failure, developed 10 new drugs.
So far, China cancer drug research and development to pursuit of developed countries such as America and Britain, still need a long time. The world health organization (who) clinical trials database to the latest data show that as of December 2016, in China related to cancer clinical trials research has 19103 projects, in the same period the number of the United States for 103800, for China's five times.
In fact, the domestic parties are spare no effort to promote Chinese medicine research and development of innovation. Last November, the domestic 12 academicians led to form a "about Suggestions to promote the development of our country independent innovation drugs", want to use this way to improve the domestic innovation medicine environment problems. The China council for the promotion of pharmaceutical innovation, executive director Song Ruilin view, the proposal to solve the problems of the three most main, one is how to use the innovation medicine with independent intellectual property rights and high quality generic drugs, complete replacement of the original in clinical medicine; 2 it is to hope to be able to improve the policy environment, break through the bottleneck restriction; Three is to reduce medical costs, reduce health care and common people's actual spending.
"Now is the best period for cancer drug development." RDPAC executive committee members Lin Tai kang said, now has more than 7000 kinds of cancer drugs in research and development, the Chinese government has issued relevant policies, investment will increase in the pharmaceutical innovation 15% a year, the resultant force increase cancer drugs technological prowess. |
